Skip to main content
. 2014 Jun;99(6):1050–1061. doi: 10.3324/haematol.2013.087205

Figure 5.

Figure 5.

In NOD/SCID mice with B-lineage ALL xenografts MV-Edm eradicates or profoundly decreases peripheral blasts leading to survival of most mice NOD/SCID mice with the common ALL xenografts #15 and #13, the pro B ALL xenograft #6 and the pre B ALL xenograft #19 received MV-Edm (“+”, n = 8), inactivated MV-Edm (“inactivated”, n = 8) or no MV-Edm (“−”, n = 8, #15 only) each d for 5 d once peripheral CD45+Ly5− leukemic blasts reached mice. 5–20 % as determined by FACS. (A) Peripheral leukemic blasts and survival. Peripheral CD45+Ly5− leukemic blasts were monitored by FACS analysis (left panels). Kaplan-Meier survival plots were generated (right panels; *** P<0.001, ns = not significant using the log rank test). (B) Leukemic burden in blood and spleen of mice with xenograft #13 markedly decreases following treatment. The percentages of CD45+Ly5− leukemic blasts in the last blood sample procured before death are compared (left panel; means +SD for each group are depicted, ***P<0.001 using the unpaired t-test). Spleens were procured after death and photographed (right panel, scale bar equals 3 cm).